StockNews.com Upgrades Sanofi (NASDAQ:SNY) to “Strong-Buy”

Sanofi (NASDAQ:SNY) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.

Several other equities analysts have also recently weighed in on the stock. Argus raised their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Trading Down 1.1 %

Shares of SNY stock opened at $57.63 on Friday. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97. The firm has a fifty day moving average price of $54.34 and a 200-day moving average price of $50.48. The company has a market cap of $145.96 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 1.62 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.95 EPS. As a group, equities analysts predict that Sanofi will post 4.25 earnings per share for the current year.

Institutional Investors Weigh In On Sanofi

A number of institutional investors have recently added to or reduced their stakes in SNY. POM Investment Strategies LLC purchased a new position in Sanofi in the second quarter worth $25,000. Frazier Financial Advisors LLC acquired a new position in Sanofi during the 4th quarter valued at about $28,000. Register Financial Advisors LLC purchased a new stake in Sanofi in the first quarter valued at about $29,000. Larson Financial Group LLC boosted its stake in Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in shares of Sanofi during the fourth quarter worth $31,000. Institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.